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Background: Plasmodium falciparum and Plasmodium vivax are endemic in Vanuatu and the Solomon Islands.
While both countries have introduced artemether-lumefantrine (AL) as first-line therapy for both P. falciparum and
P. vivax since 2008, chloroquine and sulphadoxine-pyrimethamine (SP) were used as first-line therapy for many years
prior to the introduction of AL. Limited data are available on the extent of SP resistance at the time of policy change.
Methods: Blood spots were obtained from epidemiological surveys conducted on Tanna Island, Tafea Province,
Vanuatu and Temotu Province, Solomon Islands in 2008. Additional samples from Malaita Province, Solomon Islands
were collected as part of an AL therapeutic efficacy study conducted in 2008. Plasmodium vivax and P. falciparum dhfr
and dhps genes were sequenced to detect nucleotide polymorphisms.
Results: All P. falciparum samples analysed (n =114) possessed a double mutant pfdhfr allele (C59R/S108N). Additionally,
mutation A437G in pfhdps was detected in a small number of samples 2/13, 1/17 and 3/26 from Tanna Island, Vanuatu
and Temotu and Malaita Provinces Solomon Islands respectively. Mutations were also common in pvdhfr from Tanna
Island, Vanuatu, where 33/51 parasites carried the double amino acid substitution S58R/S117N, while in Temotu and
Malaita Provinces, Solomon Islands 32/40 and 39/46 isolates carried the quadruple amino acid substitution F57L/S58R/
T61M/S117T in DHFR respectively. No mutations in pvdhps (n =108) were detected in these three island groups.
Conclusion: Prior to the introduction of AL, there was a moderate level of SP resistance in the P. falciparum population
that may cause SP treatment failure in young children. Of the P. vivax isolates, a majority of Solomon Islands
isolates carried quadruple mutant pvdhfr alleles while a majority of Vanuatu isolates carried double mutant pvdhfr
alleles. This suggests a higher level of SP resistance in the P. vivax population in Solomon Islands compared to
the sympatric P. falciparum population and there is a higher level of SP resistance in P. vivax parasites from
Solomon Islands than Vanuatu. This study demonstrates that the change of treatment policy in these countries
from SP to ACT was timely. The information also provides a baseline for future monitoring.
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Both Plasmodium falciparum and Plasmodium vivax are
endemic in Vanuatu (except for the islands of Aneityum
and Futuna which are malaria free) and the Solomon
Islands. Malaria transmission throughout Vanuatu and
the Solomon Islands occurs year round with varying de-
grees of seasonal intensity. In Vanuatu, transmission peaks
from December to April, while in the Solomon Islands
there are two transmission peaks, April to September and
November to February. Over the past decade malaria inci-
dence rates have declined, and today, both countries are
intensifying malaria control country wide and progressing
towards malaria elimination in targeted provinces.
The success of malaria control and elimination programs
in these countries relies on effective treatment of malaria
cases and asymptomatic carriers. Historically, both coun-
tries used chloroquine (CQ) for treatment of uncompli-
cated P. falciparum malaria. Chloroquine-resistance (CQR)
in P. falciparum was first reported in the early 1980s [1]
and subsequent loss of CQ efficacy forced a treatment
policy change in the Solomon Islands and Vanuatu [2].
In 1994, the Vanuatu Ministry of Health (MOH) intro-
duced a combination therapy of CQ and sulphadoxine-
pyrimethamine (SP) for treatment of uncomplicated P.
falciparum infection, while CQ remained the prescribed
treatment for P. vivax infections [2]. Similarly, in the
Solomon Islands throughout the 1990s the combination
of CQ + SP was used as second-line treatment and later
from 2001 to 2007, as first-line treatment [2].
In 2008–2009, following WHO recommendation,
Vanuatu and the Solomon Islands introduced artemether-
lumefantrine (AL) as first-line treatment for uncompli-
cated falciparum malaria, and AL plus primaquine for
treatment of malaria caused by P. vivax [3]. These are two
of the few countries where AL is used to treat both vivax
and falciparum malaria, however there was limited infor-
mation on the extent of parasite resistance to CQ and SP
at the time of AL implementation.
SP is one of the most extensively used anti-malarials
throughout the world; the SP drug combination primarily
targets dihydrofolate reductase (DHFR) and dihydroptero-
ate synthase (DHPS), critical enzymes in the folate biosyn-
thetic pathway of the malarial parasite, thereby killing the
parasite. However, parasites rapidly develop resistance to
SP through single nucleotide polymorphisms (SNPs) in
the genes encoding DHFR and DHPS enzymes [4-6]. Drug
resistant mutations occurring mainly in five amino acid
residues situated close to the active site on the P. falcip-
arum DHFR (A16V, N51I, C59R, S108N/T and I164L)
and in four amino acid positions (F57I/L, S58R, T61M
and S117T/N) in P. vivax DHFR have been widely re-
ported [7-13]. Combinations of these mutations correlate
with varying levels of SP resistance in parasites. Mutations
in P. falciparum DHPS (S436A, A437G, K540E, A581Gand A613S/T) confer resistance to sulphadoxine [6].
Analogous mutations in the P. vivax DHPS gene have also
been determined (A383G, A553G and V585) [14,15].
The ability to monitor for mutations in the P. falcip-
arum and P. vivax dhfr and dhps genes provides a valuable
method of epidemiological surveillance of SP resistance.
For instance, areas experiencing higher levels of SP pres-
sure tend to exhibit increased prevalence of pvdhfr mutant
alleles while those areas under little or no SP pressure are
more likely to maintain the wild-type pvdhfr genotype
[10,11]. Since the introduction of SP in early 1990s, two
surveys have been conducted in Guadalcanal, Solomon
Islands (1995–1996 [13], 2004–2005 [16]) and Malo
Island, Vanuatu (1996–1998 [13], 2005 [17]). However,
due to fragmented land masses in both countries, parasite
population and drug resistance profiles could be very dif-
ferent between different islands.
This paper describes prevalence of P. falciparum and
P. vivax parasites resistant to SP in three areas of
Vanuatu and Solomon Islands prior to the implementa-
tion of AL. The data and results reported here provide
excellent baseline information on the status of SP resist-
ant mutations in parasite populations prior to changes
in treatment guidelines. The information also enables in-
vestigations into evolution of SP resistance in P. falcip-
arum and P. vivax populations following a parallel
change of treatment policy in areas where both Plasmo-
dium species co-exist.
Methods
Study areas and sample collection
Three sets of blood samples were used in this study. Two
sets were obtained from epidemiological surveys con-
ducted (2008) during the wet seasons in Tafea Province,
Vanuatu and Temotu Province, Solomon Islands, the geo-
graphic locations and information regarding the demo-
graphics of the populations surveyed and consent process
have been published previously [18]. In brief, a school-
based, mass blood survey of children (2–12 years) was
performed on Tanna Island, Tafea Province which is the
most southern Province of Vanuatu. In this study speci-
ation by PCR identified 42 samples positive for P. falcip-
arum infection, 92 for P. vivax infection and 10 for mixed
P. falciparum/P. vivax infections. Similarly, a village-based
mass blood survey encompassing all ages was conducted
on Temotu Province, the most southern Province in the
Solomon Islands which is made up of five main island
groups: Santa Cruz, Reef Islands, Duff Islands, Utupua
Island and Vanikoro Island. In this study PCR identified
118 P. falciparum infections, 162 P. vivax infections and
39 mixed P. falciparum/P. vivax infections. The third set
of samples was obtained from febrile patients attending
Auki town clinic and Kilu’Ufi hospital, Malaita Province,
Solomon Islands through collaboration with the World
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Solomon Islands. These samples were collected as part of
an artemether-lumefantrine (AL, Coartem™, Novartis) effi-
cacy study conducted within the Solomon Islands planned
and executed by the WHO and MOH Solomon Islands.
Malaita Province lies approximately 9°S 161°E and is
the second largest and most densely populated Province
of the Solomon Islands. In this study PCR identified 68
P. falciparum infections, 31 P. vivax infections and 37
mixed P. falciparum/P. vivax infections. Across all
study sites blood samples were collected by finger prick
and a blood spot (20–30 μL) was air-dried onto filter
paper (Whatman No. 3), sealed in individual plastic bags
containing desiccant and stored at room temperature until
further processing.
Extraction of parasite DNA
Genomic DNA was extracted from blood samples that
were P. falciparum or P. vivax positive by microscopy
using QIAGEN QIAamp DNA Mini Kits and a QIAcube
robot (QIAGEN, Crawley, U.K.). The manufacturer’s
protocol (QIAamp DNA Mini and Blood Mini Hand-
book 2E) was followed with the modifications that only
one 5 mm circle was extracted and each sample was
eluted using 100 μL of AE buffer.
Confirmation of Plasmodium spp.
Plasmodium speciation was performed by multiplex PCRs
[19] (P. falciparum, P. vivax, Plasmodium ovale or Plasmo-
dium malariae) followed by a confirmatory single species
PCR, as previously described [18,20].
Amplification of dhfr and dhps genes
Approximately 30% of PCR confirmed Plasmodium posi-
tive samples were selected at random for DNA sequence
analysis. These samples were being used for several dif-
ferent studies, we were therefore limited in the number
of samples we were able to analyse. DNA fragments of
the dhfr and dhps genes of P. falciparum and P. vivax
encompassing sites of known mutations were amplified by
nested PCR as described previously [6,14,21,22]. PCR
products were purified using ExoSAP-ITR (USB, Cleveland,
OH) to remove excess primers and nucleotides according
to the manufacturer’s protocol and then sequenced.
Sequencing was performed using Big Dye Terminator
(v.3.1) on an automated DNA sequencer, ABI 3100 sys-
tem, at the QIMR Berghofer Medical Research Insti-
tute Scientific Services Analytical Facility. In cases
where PCR products contained multiple bands, a sin-
gle band of expected size was excised from an agarose
gel and purified using a NucleoSpinR extraction kit
(Macherey-Nagel) and then sequenced. Sequence poly-
morphisms were determined by alignment.Results
Mutations in P. falciparum DHFR and DHPS
The dhfr and dhps genes of P. falciparum were amplified
and sequenced from randomly selected samples from all
three island groups. The number of samples sequenced for
these genes are detailed in Table 1. Sequencing analysis of
pfdhfr revealed all isolates (n = 114) from all three island
groups exhibited amino acid substitutions C59R and
S108N having an allelic type ACRNI. Analysis of pfdhps re-
vealed that 11/13, 16/17 and 23/26 samples were of wild
type allele SAKAA, from Tanna Island, Vanuatu and
Temotu and Malaita Provinces Solomon Islands, respect-
ively. In addition one sample from Tanna Island, Vanuatu
and three samples from Malaita Province, Solomon Islands
possessed a single A437G substitution while one sample
from Port Resolution on Tanna Island, Vanuatu was identi-
fied with a double substitution A437G +A581G. Further-
more, one sample from Utupua Island, Temotu Province,
Solomon Islands carried a rare but widespread S436F mu-
tation in conjunction with A437G and A613S substitutions
resulting in a triple mutant allele FGKAS (Table 1).
Mutations in Plasmodium vivax DHFR and DHPS
On Tanna Island, Vanuatu, 33/51 P. vivax isolates carried
a double mutant pvdhfr allele with substitutions S58R/
S117N. A further eleven isolates were triple mutant alleles
PMSTTF, containing a novel F57M substitution, while the
remaining seven isolates were double mutant alleles
PLSTSF. In Temotu Province, Solomon Islands there was
a high incidence of samples containing mixed strains;
these were excluded from further analysis. The dominant
allele occurring in 32/40 samples was the pvdhfr quadru-
ple mutant allele PLRMTI. Of the remaining isolates, four
were single mutant alleles S117N, three were triple mutant
alleles PLRTTI and one was a triple mutant allele PLRTSM.
In contrast to pvdhfr, all P. vivax isolates (n = 108) analysed
from all three regions possessed only a wild type pvdhps al-
lele SAKAV in conjunction with one or more mutations in
pvdhfr (Table 2).
Similarly, in Malaita Province, Solomon Islands, 39/46
isolates carried a pvdhfr quadruple mutant allele PLRMTI.
A further three samples were triple mutant alleles
PLRTSM carrying a novel I173M mutation, with another
two samples identified as double mutant alleles PFRA-
GATNI. The remaining allelic types consisted of single iso-
lates PLRTNI and PFRAGATTI. Interestingly, in Malaita
Province, Solomon Islands, three samples possessed a
S58R substitution where the arginine residue was coded
by AGA, whereas in Temotu Province and Tanna Island,
Vanuatu the arginine was solely coded by AGG (Table 2).
Discussion
Vanuatu and the Solomon Islands are among the few coun-
tries where ACT is used for treatment of both P. falciparum
Table 1 Amino acid substitutions (bold) and prevalence
in P. falciparum DHFR and DHPS from Vanuatu and
Solomon Islands
PfDHFR
Amino acid position n Frequency 16 51 59 108 164
Wild type A N C S I
Known substitutions in the
region
V I R N/T L
Country Island/province
Vanuatu Tanna Is. 22 22 A C R N I
Solomon Is Temotu Prov. 34 34 A C R N I
Malaita Prov. 58 58 A C R N I
Pf DHPS
Amino acid position n Frequency 436 437 540 581 613
Wild type S A K A A
Known substitutions in the
region
A/F G E G S/T
Country Island/province
Vanuatu Tanna Is. 13 11 S A K A A
1 S G K A A
1 S G K G A
Solomon Is Temotu Prov. 17 16 S A K A A
1 F G K A S
Malaita Prov. 26 23 S A K A A
3 S G K A A
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resistance profile at the time of ACT introduction al-
lows for the detection of changes in future parasite
populations. Although it is not clear whether parasites
carrying mutant dhfr and dhps alleles have a selective
advantage or disadvantage under AL pressure, the aim
of this paper was to determine the base line polymor-
phisms of pfdhfr, pfhdps, pvdfr and pvdhps at the time
of AL introduction in three island groups not previ-
ously surveyed.
Results of this study indicated that 100% of P. falcip-
arum and P. vivax isolates from three island groups in
Vanuatu and the Solomon Islands had point mutations
in the gene coding for DHFR that are associated with
antifolate resistance. In contrast, an average of 88.6% of
P. falciparum isolates and 100% of P. vivax isolates pos-
sessed a wild type dhps gene. The differences in the
prevalence of mutations between DHFR and DHPS sup-
ports the asymmetric selection pattern previously re-
ported [7] to occur in both species in these areas.
A double mutant pfdhfr allele, C59R/S108N, was
detected in 100% of P. falciparum isolates tested from
all three island groups. This pattern and fixation is simi-
lar to that reported for parasites collected on different
islands to this study in the mid1990s and in 2005[13,16,17]. Based on earlier studies, point mutation
S108N alone is sufficient to confer resistance to pyri-
methamine [5,23-25], the addition of a C59R mutation
in conjunction with S108N would result in a sizeable in-
crease in the levels of resistance to pyrimethamine
[5,23-25]. Although this double mutant allele does not
confer SP resistance levels as high as the quadruple mu-
tant alleles [26], in some studies it has been implicated
in treatment failures in young children [27,28], while
other studies indicate minimal SP treatment failures
[29,30]. The fixation of double mutant pfdhfr alleles in P.
falciparum populations in Vanuatu and Solomon Islands
indicates that children infected with P. falciparum could
potentially experience treatment failure if SP usage was
continued.
Previously published findings at different island loca-
tions in Vanuatu and Solomon Islands reported only
wild type pfdhps alleles [13,16,17]. In this study, al-
though a majority of the P. falciparum isolates (50/56)
from all three island groups had a wild type pfdhps, a
small number of samples (6) possessed an A437G muta-
tion. The pfdhps A437G mutation is often observed in
regions where SP has been widely used and its presence
alone, although more commonly when combined with
mutation K540E and a triple DHFR mutation, is predict-
ive of early SP treatment failure [7,28,31]. In this study,
no mutations were detected at amino acid position 540
of pfdhps in any of the samples investigated. This is not
unexpected since earlier studies have indicated that the
presence of K540E is often associated in the quintuple
haplotype including three mutations in pfdhfr and two
mutations in pfdhps [31]. Interestingly, one sample from
Port Resolution on Tanna Island, Vanuatu was identified
as carrying a double mutant pfdhps allele A437G and
A581G. This suggests that parasite populations were ex-
posed to SP pressure since A581G is reported to in-
crease in frequency with extended SP usage [32]. It is
also possible that this parasite isolate was imported from
other areas because the village is located in a busy port
serving inter-island sea travel.
The occurrence of double, triple and quadruple muta-
tions in pvdhfr were observed in isolates from Tanna
Island, Vanuatu as well as Temotu and Malaita Provinces,
Solomon Islands. In Vanuatu the dominant allele occur-
ring in 64% of isolates was the double mutant allele
PNFRTNI, whereas in Malaita and Temotu Provinces,
Solomon Islands, the dominant allele was the quadruple
mutant allele PNLRMTI occurring in 85% and 80% of
isolates, respectively. Amino acid codon 117 of pvdhfr
has been reported to mutate to either an asparagine (N)
or threonine (T). While S117N has been associated with
reduced in vitro susceptibility to pyrimethamine it has
not been reported to associate with the highly resistant
quadruple mutant alleles, and has therefore been
Table 2 Amino acid substitutions (bold) and prevalence in P. vivax DHFR and DHPS from Vanuatu and Solomon Islands
PvDHFR
Amino acid position n Frequency 33 57 58 61 117 173
Wild type P F S T S I
Known substitutions in the region L I/L R N T/N L
Country Island/province
Vanuatu Tanna Is. 51 33 P F R T N I
11 P M S T T F
7 P L S T S F
Solomon Is Temotu Prov. 40 32 P L R M T I
4 P F S T N I
3 P L R T T I
1 P L R T S M
Malaita Prov. 46 39 P L R M T I
3 P L R T S M
2 P F RAGA T N I
1 P L R T N I
1 P F RAGA T T I
PvDHPS
Amino acid position n Frequency 382 383 512 553 585
Wild type S A K A V
Known substitutions in the region G G
Country Island/province
Vanuatu Tanna Is. 38 38 S A K A V
Solomon Is Temotu Prov. 22 22 S A K A V
Malaita Prov. 48 48 S A K A V
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In contrast, the S117T mutation has been associated
with quadruple mutant alleles and clinical resistance to
SP [22,33]. On the other hand, the pvdhfr double mu-
tants S58R + S117N are usually associated with delayed
parasite clearance after SP treatment, not failure. This
indicates that P. vivax isolates in Solomon Islands may
have been under more extensive selection pressure than
those in Tanna Island, Vanuatu. Mass drug administra-
tion of chloroquine and primaquine was one of the key
preventive strategies used by the Malaria Eradication
Programme in Solomon Islands from 1974 [34] to the
early 1990s.
Interestingly only wild type pvdhps alleles were de-
tected in isolates from all three island groups. All P.
vivax isolates had V585 that was previously reported to
play a major role in the innate resistance of this parasite
to sulphadoxine [14].
Conclusion and implications
This study provides baseline data on the extent of SP
drug resistance in P. vivax and P. falciparum parasites in
these three island groups prior to the introduction ofACT. In summary, 100% of P. falciparum parasites car-
ried a double mutant pfdhfr allele with a small propor-
tion of these also carrying a single or double dhps
mutation. This indicates a moderate level of SP resist-
ance in the P. falciparum populations that may cause SP
treatment failure in young children. Similarly 100% of P.
vivax isolates carried mutant pvdhfr alleles: a dominant
double mutant allele in Vanuatu and a dominant quad-
ruple mutant allele in Solomon Islands. It is speculated
that P. vivax has developed a higher level of SP resist-
ance in Solomon Islands compared to the sympatric
P. falciparum population, and there is a higher level of
SP resistance in P. vivax parasites from Solomon Islands
than Vanuatu. This study demonstrates that the change
of treatment policy from CQ + SP to ACT was timely.
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